[go: up one dir, main page]

MX2013003884A - Metodo para activar celulas auxiliares. - Google Patents

Metodo para activar celulas auxiliares.

Info

Publication number
MX2013003884A
MX2013003884A MX2013003884A MX2013003884A MX2013003884A MX 2013003884 A MX2013003884 A MX 2013003884A MX 2013003884 A MX2013003884 A MX 2013003884A MX 2013003884 A MX2013003884 A MX 2013003884A MX 2013003884 A MX2013003884 A MX 2013003884A
Authority
MX
Mexico
Prior art keywords
molecule
hladrb1
drb1
hla
cell
Prior art date
Application number
MX2013003884A
Other languages
English (en)
Other versions
MX361299B (es
Inventor
Yoshihiro Goto
Haruo Sugiyama
Shinji Sogo
Masayoshi Sato
Ryuki Kitamoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2013003884A publication Critical patent/MX2013003884A/es
Publication of MX361299B publication Critical patent/MX361299B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para activar las células T auxiliares, que comprende el paso de activar las células T auxiliares agregando un péptido WT1 a las células que presentan antígenos, en donde el péptido WT1 tiene la capacidad de unirse a cualquier moléculas MHC Clase II de una molécula HLA-DRB1* 0101, una molécula HLADRB1* 0401, una molécula HLADRB1* 0403, una molécula HLADRB1* 0406, una molécula HLA-DRB1* 0803, una molécula HLADRB1* 0901, una molécula HLA10 DRB1* 1101, una molécula HLADRB3* 0202, una molécula HLADRB4* 0101, una molécula HLA-DPB1 0201, o una molécula HLADPB1* 0301.
MX2013003884A 2010-10-05 2011-10-04 Metodo para activar celulas auxiliares. MX361299B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
PCT/JP2011/072874 WO2012046730A1 (ja) 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法

Publications (2)

Publication Number Publication Date
MX2013003884A true MX2013003884A (es) 2013-07-05
MX361299B MX361299B (es) 2018-11-30

Family

ID=45927725

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013003884A MX361299B (es) 2010-10-05 2011-10-04 Metodo para activar celulas auxiliares.
MX2018008436A MX2018008436A (es) 2010-10-05 2013-04-05 Metodo para activar celulas t auxiliares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008436A MX2018008436A (es) 2010-10-05 2013-04-05 Metodo para activar celulas t auxiliares.

Country Status (21)

Country Link
US (2) US10654892B2 (es)
EP (1) EP2626418B8 (es)
JP (3) JP6134139B2 (es)
KR (3) KR20140009168A (es)
CN (2) CN105802910A (es)
AR (1) AR083295A1 (es)
AU (1) AU2011313327B2 (es)
BR (1) BR112013008230A2 (es)
CA (1) CA2813557C (es)
CO (1) CO6710946A2 (es)
EA (1) EA037547B1 (es)
ES (1) ES2849187T3 (es)
IL (2) IL225536B (es)
MX (2) MX361299B (es)
MY (1) MY170306A (es)
NZ (2) NZ609460A (es)
PH (1) PH12013500654A1 (es)
SG (3) SG10201508252PA (es)
TW (2) TWI608099B (es)
WO (1) WO2012046730A1 (es)
ZA (1) ZA201303056B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
KR20140009168A (ko) * 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
JP6530192B2 (ja) * 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2898099C (en) 2013-01-15 2025-09-16 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 Peptides and Their Methods of Use
CA2907782C (en) 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
HK1243960A1 (zh) 2014-12-25 2018-07-27 International Institute Of Cancer Immunology, Inc. T细胞群的改变方法
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
WO2018088439A1 (ja) 2016-11-09 2018-05-17 国立大学法人大阪大学 Ｔ細胞集団の改変方法
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
CN111741972A (zh) * 2017-12-27 2020-10-02 大日本住友制药株式会社 Wt1衍生肽的缀合物和包含其的组合物
WO2019160099A1 (ja) * 2018-02-15 2019-08-22 大塚製薬株式会社 がん抗原ペプチド
MX2021001938A (es) * 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
KR100752065B1 (ko) 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
NZ521430A (en) 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP2014300B1 (en) 2001-06-29 2011-01-12 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome
WO2003028758A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
ES2332590T3 (es) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
CN1842603B (zh) 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 选择适于wt1疫苗患者的方法
CN100513563C (zh) * 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
SI1988163T1 (sl) 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2670658A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
CA2677075C (en) * 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
CN103374576A (zh) 2007-03-05 2013-10-30 株式会社癌免疫研究所 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
KR20140009168A (ko) * 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法

Also Published As

Publication number Publication date
JP6298101B2 (ja) 2018-03-20
ZA201303056B (en) 2013-12-23
EP2626418B1 (en) 2020-12-09
MX361299B (es) 2018-11-30
MX2018008436A (es) 2021-12-08
NZ703560A (en) 2016-11-25
KR20190034359A (ko) 2019-04-01
WO2012046730A1 (ja) 2012-04-12
CN103298928B (zh) 2016-04-20
IL225536B (en) 2019-03-31
CN105802910A (zh) 2016-07-27
EP2626418B8 (en) 2021-03-24
AR083295A1 (es) 2013-02-13
ES2849187T3 (es) 2021-08-16
SG10201508252PA (en) 2015-11-27
NZ609460A (en) 2015-07-31
CO6710946A2 (es) 2013-07-15
CA2813557C (en) 2021-05-04
SG10202108581TA (en) 2021-09-29
CN103298928A (zh) 2013-09-11
EA037547B1 (ru) 2021-04-12
US12415833B2 (en) 2025-09-16
SG189287A1 (en) 2013-05-31
TWI608099B (zh) 2017-12-11
CA2813557A1 (en) 2012-04-12
AU2011313327B2 (en) 2015-10-22
BR112013008230A2 (pt) 2016-06-14
EP2626418A1 (en) 2013-08-14
US10654892B2 (en) 2020-05-19
JP6134139B2 (ja) 2017-05-24
KR102171794B1 (ko) 2020-10-29
PH12013500654A1 (en) 2013-05-06
IL245440A0 (en) 2016-06-30
IL225536A0 (en) 2013-06-27
US20200354405A1 (en) 2020-11-12
JPWO2012046730A1 (ja) 2014-02-24
TW201623616A (zh) 2016-07-01
EP2626418A4 (en) 2014-02-19
MY170306A (en) 2019-07-17
KR20200018738A (ko) 2020-02-19
TW201217525A (en) 2012-05-01
KR102079480B1 (ko) 2020-02-19
JP2018093870A (ja) 2018-06-21
EA201390509A1 (ru) 2013-08-30
AU2011313327A1 (en) 2013-05-02
US20130266958A1 (en) 2013-10-10
KR20140009168A (ko) 2014-01-22
JP2017006120A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
MX2013003884A (es) Metodo para activar celulas auxiliares.
MX2015007745A (es) Metodo para activar la celula t auxiliar.
CO6470802A2 (es) Péptido auxiliar del antígeno del cáncer
BR112012006912A8 (pt) Hipervesiculação de cepas de shigella
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
MX2009009168A (es) Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
BR112014016032A8 (pt) método para separação de gases
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
CR20110204A (es) Moleculas de anticuerpo mejoradas
BR112013004341A2 (pt) composições pesticidas
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
BR112016003127A2 (pt) “composições e métodos para modular rna”
CY1115595T1 (el) Αλατα ρασιγιλινης και φαρμακευτικη παρασκευη αυτων
BR112014001834A2 (pt) biocontrole de nematoides
CY1119173T1 (el) Νεα μορια αναστολεα jnk
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
BR112014026900A2 (pt) óleos com alto teor de ácido oleico
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
CL2009001082A1 (es) Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.
CO6450617A2 (es) Produccion de hidrocarburos de isopreno mejorada que usa cianobacterias diseñadas geneticamente
BR112015009301A2 (pt) biocontrole de nematoides
BR112015012681A2 (pt) método para aprimorar uma cepa de levedura de interesse industrial, uso do processo de levedura rtg para aprimorar uma cepa de levedura de interesse industrial, método para geração de uma biblioteca recombinante de levedura a partir de uma levedura, biblioteca de leveduras recombinantes e método para identificar ou localizar, em uma levedura, a informação genética que codifica uma característica de interesse

Legal Events

Date Code Title Description
FG Grant or registration